Management team

Eva Arlander
Born in 1964. MSc Pharm and PhD.
Vice President Medivir Pharma and Project Director for Xerclear. Employed since 2004. Previous employment includes positions within Clinical Research and Development at AstraZeneca.  Number of Medivir shares:0
Stock options* 2004-2009: 2,400
Stock options** 2005 – 2010: 2,500
Stock options 2007 – 2012: 12,000

Christina Kassberg
Born in 1968. BSc, Bachelor of Science in Business. Vice President, Business Control and Administration.
Employed since 2000. Previous employment includes Controller Medivir AB , responsible for finance and accounting, Skandia Link Multifond and auditor Öhrling Pricewaterhouse Coopers.
Number of Medivir shares: 4,104 class B (including family holdings)
Stock options* 2004 – 2009: 2,000
Stock options** 2005 – 2010: 2,000
Stock options 2007 – 2012: 20,000

Ron Long
Born in 1947. BA Reading University.
CEO and President since 2009. Previous experience including positions within Wellcome Foundation Plc, Amersham Pharmacia AB, Kudos Pharmaceuticals and board member of Biacore AB and Automation Partnership Plc.
Number of Medivir shares: 10,975 class B.

Iain Morrison
Born 1960, LL.B, B.Sc(Hons), Auth. IP Attorney, Vice President Legal Affairs.
Employed since 1993. Formerly practiced as solicitor and patent attorney in large law firms in Australia and Sweden.
Number of Medivir shares: 0.
Stock options* 2004 - 2009: 2,200
Stock options** 2005 - 2010: 2,500
Stock options 2007 – 2012: 6,000

Rein Piir
Born in 1958. B.Sc. (Econ.) Chief Financial
Officer/Vice President, Investor Relations.
Employed since 2000.
Previous employment includes senior positions in Healthcare & Research at D. Carnegie AB and Research & Strategy at SPP.
Number of Medivir shares: 0.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,000
Stock options 2007 – 2012: 20,000

Bertil Samuelsson
Born in 1950. Ph.D., Professor. Vice President, Discovery Research. Employed since 1999.
Previous employment includes Head of Medicinal Chemistry, AstraZeneca, Mölndal, Sweden.
Number of shares in Medivir (including family
holdings): 40,460 class B.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,500
Stock options 2007 – 2012: 22,000

Paul Wallace
Born in 1962. Ph.D. University of Cambridge,
Vice President, Business Development.
Employed since 2000.
Previously Business Development Manager
at Peptide Therapeutics plc and Director of Research at Eclagen, both in the UK.
Number of Medivir shares: 0.
Stock options* 2004 - 2009: 4,800
Stock options** 2005 - 2010: 7,500
Stock options 2007 – 2012: 22,000

* Outstanding options
There were 970,000 outstanding options at the end of the year, corresponding to 1,102,300 class B shares. No options were converted or expired in the year. The number of outstanding options could increase shareholders’ equity by sek 82.9 m and upon full conversion, the total number of shares could amount to 21,945,847.

** As above, apart from the first one-third not being exercisable until two years after the date of apportionment.